Cargando…
Population Pharmacokinetics and Exposure‐Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β‐Thalassemia
β‐Thalassemia is an inherited blood disorder resulting from defects in hemoglobin production, leading to premature death of red blood cells (RBCs) or their precursors. Patients with transfusion‐dependent β‐thalassemia often need lifelong regular RBC transfusions to maintain adequate hemoglobin level...
Autores principales: | Chen, Nianhang, Kassir, Nastya, Laadem, Abderrahmane, Giuseppi, Ana Carolina, Shetty, Jeevan, Maxwell, Stephen E., Sriraman, Priya, Ritland, Steve, Linde, Peter G., Budda, Balasubrahmanyam, Reynolds, Joseph G., Zhou, Simon, Palmisano, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754485/ https://www.ncbi.nlm.nih.gov/pubmed/32696522 http://dx.doi.org/10.1002/jcph.1696 |
Ejemplares similares
-
Population Pharmacokinetics and Exposure–Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes
por: Chen, Nianhang, et al.
Publicado: (2020) -
Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: Disposition kinetics and pharmacology distinct from solvent-based paclitaxel
por: Chen, Nianhang, et al.
Publicado: (2014) -
Population Pharmacokinetics of Tenecteplase in Patients With Acute Myocardial Infarction and Application to Patients With Acute Ischemic Stroke
por: Tang, Fei, et al.
Publicado: (2022) -
Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
por: Piga, Antonio, et al.
Publicado: (2022) -
Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)